Association Between the Risk of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease

References

• Guo L. Prevalence of diabetes and coping strategies. Chin J Clin Healthcare. 2020;23(4):433–436.
   Google Scholar
• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi:10.1038/nrendo.2017.151
   PubMed Web of Science ®Google Scholar
• Lee YJ, Wang CP, Hung WC, et al. Common and unique factors and the bidirectional relationship between chronic kidney disease and nonalcoholic fatty liver in type 2 diabetes patients. Diabetes Metab Syndr Obes. 2020;13:1203–1214. doi:10.2147/DMSO.S237700
   PubMed Web of Science ®Google Scholar
• Tong L, Adler SG. Diabetic kidney disease. Clin J Am Soc Nephrol. 2018;13(2):335–338. doi:10.2215/CJN.04650417
   Web of Science ®Google Scholar
• Litwak L, Goh SY, Hussein Z, et al. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. Diabetol Metab Syndr. 2013;5(1):57. doi:10.1186/1758-5996-5-57
   PubMed Web of Science ®Google Scholar
• de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532–2539. doi:10.1001/jama.2011.861
   PubMed Web of Science ®Google Scholar
• Hu Y, Shi R, Mo R, et al. Nomogram for the prediction of diabetic nephropathy risk among patients with type 2 diabetes mellitus based on a questionnaire and biochemical indicators: a retrospective study. Aging. 2020;12(11):10317–10336. doi:10.18632/aging.103259
   PubMedGoogle Scholar
• Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19(8):1564–1570. doi:10.1681/ASN.2007101155
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu S, Li B, et al. Association between non-alcoholic fatty liver disease and chronic kidney disease in population with prediabetes or diabetes. Int Urol Nephrol. 2014;46(9):1785–1791. doi:10.1007/s11255-014-0796-9
   PubMed Web of Science ®Google Scholar
• Jang HR, Kang D, Sinn DH, et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep. 2018;8(1):4718. doi:10.1038/s41598-018-23014-0
   PubMed Web of Science ®Google Scholar
• Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686–690. doi:10.1038/nrgastro.2013.171
   PubMed Web of Science ®Google Scholar
• Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–344. doi:10.1038/nrgastro.2013.41
   PubMed Web of Science ®Google Scholar
• Targher G, Chonchol M, Zoppini G, et al. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol. 2011;54(5):1020–1029. doi:10.1016/j.jhep.2010.11.007
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Adams LA, Canbay A, et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59(3):1174–1197. doi:10.1002/hep.26717
   PubMed Web of Science ®Google Scholar
• Sinn DH, Kang D, Jang HR, et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study. J Hepatol. 2017;67(6):1274–1280. doi:10.1016/j.jhep.2017.08.024
   PubMed Web of Science ®Google Scholar
• Afarideh M, Aryan Z, Ghajar A, et al. Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes. Prim Care Diabetes. 2019;13(6):505–514. doi:10.1016/j.pcd.2019.03.009
   PubMed Web of Science ®Google Scholar
• Kim BY, Jung CH, Mok JO, et al. Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease. J Diabetes Investig. 2014;5(2):170–175. doi:10.1111/jdi.12139
   Web of Science ®Google Scholar
• Zhan YT, Zhang C, Li L, et al. Non-alcoholic fatty liver disease is not related to the incidence of diabetic nephropathy in type 2 diabetes. Int J Mol Sci. 2012;13(11):14698–14706. doi:10.3390/ijms131114698
   Web of Science ®Google Scholar
• Jha JC, Banal C, Chow BS, et al. Diabetes and kidney disease: role of oxidative stress. Antioxid Redox Signal. 2016;25(12):657–684. doi:10.1089/ars.2016.6664
   PubMed Web of Science ®Google Scholar
• Cojocariu C, Singeap AM, Girleanu I, et al. Non-alcoholic fatty liver disease-related chronic kidney disease. Can J Gastroenterol Hepatol. 2020;4:20206630296.
   Google Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254. doi:10.7326/0003-4819-145-4-200608150-00004
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51(3):444–450. doi:10.1007/s00125-007-0897-4
   PubMed Web of Science ®Google Scholar
• Hwang ST, Cho YK, Yun JW, et al. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J. 2010;40(6):437–442. doi:10.1111/j.1445-5994.2009.01979.x
   Web of Science ®Google Scholar
• Yang L, Chu TK, Lian J, et al. Risk factors of chronic kidney diseases in Chinese adults with type 2 diabetes. Sci Rep. 2018;8(1):14686. doi:10.1038/s41598-018-32983-1
   Web of Science ®Google Scholar
• Bril F, Cusi K. Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus. Endocrinol Metab Clin North Am. 2016;45(4):765–781. doi:10.1016/j.ecl.2016.06.005
   PubMed Web of Science ®Google Scholar
• Masarone M, Rosato V, Aglitti A, et al. Liver biopsy in type 2 diabetes mellitus: steatohepatitis represents the sole feature of liver damage. PLoS One. 2017;12(6):e0178473. doi:10.1371/journal.pone.0178473
   PubMed Web of Science ®Google Scholar
• Kanbay M, Bulbul MC, Copur S, et al. Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease. J Nephrol. 2021;34(3):649–659. doi:10.1007/s40620-020-00751-y
   Web of Science ®Google Scholar
• Rinaldi L, Pafundi PC, Galiero R, et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A Narrative Review Antioxidants. 2021;10(2):270.
   Web of Science ®Google Scholar
• Marcuccilli M, Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci. 2016;17(4):562. doi:10.3390/ijms17040562
   PubMed Web of Science ®Google Scholar
• Maliakkal BJ. Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation. Transl Gastroenterol Hepatol. 2020;5:36. doi:10.21037/tgh.2019.12.02
   Web of Science ®Google Scholar
• Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32–42. doi:10.1038/nrgastro.2016.147
   PubMed Web of Science ®Google Scholar
• Valenti L, Bugianesi E, Pajvani U, et al. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver Int. 2016;36(11):1563–1579. doi:10.1111/liv.13185
   PubMed Web of Science ®Google Scholar
• de Boer IH, Rue TC, Cleary PA, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Arch Intern Med. 2011;171(5):412–420. doi:10.1001/archinternmed.2011.16
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG. Diabetic nephropathy: new risk factors and improvements in diagnosis. Rev Diabetic Stud. 2015;12(1–2):110–118. doi:10.1900/RDS.2015.12.110
   PubMedGoogle Scholar
• Galiero R, Caturano A, Vetrano E, et al. Pathophysiological mechanisms and clinical evidence of relationship between nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. Rev Cardiovasc Med. 2021;22(3):755–768. doi:10.31083/j.rcm2203082
   Web of Science ®Google Scholar
• Minutolo R, Sasso FC, Chiodini P, et al. Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings. J Hypertens. 2006;24(8):1655–1661. doi:10.1097/01.hjh.0000239303.93872.31
   PubMed Web of Science ®Google Scholar
• Sasso FC, Pafundi PC, Simeon V, et al. Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovasc Diabetol. 2021;20(1):145. doi:10.1186/s12933-021-01343-1
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Cohney S, et al. Emerging liver-kidney interactions in nonalcoholic fatty liver disease. Trends Mol Med. 2015;21(10):645–662. doi:10.1016/j.molmed.2015.08.005
   PubMed Web of Science ®Google Scholar
• Sanchez-Niño MD, Bozic M, Córdoba-Lanús E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2012;302(6):F647–657. doi:10.1152/ajprenal.00090.2011
   PubMed Web of Science ®Google Scholar
• Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018;71(6):884–895. doi:10.1053/j.ajkd.2017.10.026
   PubMed Web of Science ®Google Scholar